US2507244A - Surgical gelatin dusting powder and process for preparing same - Google Patents

Surgical gelatin dusting powder and process for preparing same Download PDF

Info

Publication number
US2507244A
US2507244A US741419A US74141947A US2507244A US 2507244 A US2507244 A US 2507244A US 741419 A US741419 A US 741419A US 74141947 A US74141947 A US 74141947A US 2507244 A US2507244 A US 2507244A
Authority
US
United States
Prior art keywords
gelatin
powder
surgical
water
approximately
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US741419A
Inventor
John T Correll
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmacia and Upjohn Co
Original Assignee
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Upjohn Co filed Critical Upjohn Co
Priority to US741419A priority Critical patent/US2507244A/en
Application granted granted Critical
Publication of US2507244A publication Critical patent/US2507244A/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/42Use of materials characterised by their function or physical properties
    • A61L15/64Use of materials characterised by their function or physical properties specially adapted to be resorbable inside the body
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/22Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
    • A61L15/32Proteins, polypeptides; Degradation products or derivatives thereof, e.g. albumin, collagen, fibrin, gelatin

Definitions

  • This invention relates to a powder, suitable for surgical use, which is absorbable by the bodies of living animals.
  • talc The most common lubricant for this use, until the present invention, has been a special sterile powdered inorganic talc.
  • This talc which is water-soluble and, by the nature of its physical structure, lubricating, allows the tight-fitting gloves to be fitted to the hand, and removed therefrom, without their rupture, and is therefore satisfactory for the surgeons immediate purpose, viz, donning the gloves Without their rupture or contamination.
  • this talc is not entirely satisfactory from the standpoint of ulterior physiological effects upon the patient being treated.
  • inert substances foreign in composition to the body, exert a deleterious effect when allowed to remain in contact with the healing surfaces of an incision.
  • This reaction called a foreign-body reaction, instigates a permanent and progressive inflammation which may cause many complications, such as adhesions.
  • Inert foreign bodies in the incision may also cause granulomatous lesions of the peritoneum, draining sinuses, scar nodules, and malfunctioning intestinal stomas.
  • an object of the present invention to provide a powder which is suitable for use as a lubricant of such surgical devices as rubber gloves, but which, being absorbable by the body fluids, does not effect complications which arise from the employment of an inert material.
  • the product of this invention is a water-insoluble, sterile, non-toxic, non-antigenic, non-tissue irritating hardened gelatin powder which is absorbable by the animal body without residue or untoward side reactions, and which is capable of safe and satisfactory lubrication of rubber articles such as the aforementioned surgical gloves.
  • the proteolytically digestible powder of the invention is prepared by suitably hardening a gelatin, either before or after reduction to a powder.
  • a gelatin solution may first be hardened either by the use of a chemical hardening agent, such as an aldehyde, or by heat, and thereafter subjected in either flake, slab, or powder form, to the synergistic action of a high-temperature treatment.
  • Gelatin flake may be suitably hardened by merely heating the same, in its flake form or after further reduction to a powder, at a temperature above about 145 degrees centigrade for a period of time between about 20 and about hours.
  • the degree to which the gelatin is changed or hardened is of critical importance, for, if the change from the original gelatin is not sufficient, the resulting product will be water-soluble or partially water-soluble and the powder will lose a certain proportion of its lubricating properties when exposed to moisture. On the other hand, if the change or hardening be carried too far, the product will no longer be susceptible to proteolytie disintegration and absorption by the body fluids, and thus, not being absorbable by the body, will cause the formation of granulomas and adhesions in the same manner as any other foreign substance. Accordingly, to determine whether the product has been suitably hardened, it should be found to be water-insoluble and proteolytically digestible.
  • the digestion time may be determined in a manner similar to that employed for determining the proteolytic absorbability of cat gut sutures, such as, for example, by exposure to either a 5.0 or 0.5 per cent pepsin solution, in which case proteolytic digestibility is usually satisfactory if complete within a period of about one-half hour and about six hours, respectively, for the two concentrations given. Beyond these limits, the product may. be unsuited. for the pre.-. scribed use.
  • the powder should not comprise any ingredients of an antigenic nature, but, while pure gelae tin with or without a minor; proportion. of aldehydic hardening agent is presentlynzonsidered' the; most satisfactory composition, other non-antigenic, sterile ingredients may beaddedjfi' l chi addition is considered desirable;
  • the hardening agent may be of any suitable type, formaldehyde bein Dre, ferred.
  • This aldehydic hardening agent may be; present in an amount not to exceed about three per cent by weight in the powdered product.
  • Any other method of hardening a gelatin solution may be'employed, p ioy dedbnly thatthe, de.- sired water-insoluble., non-antigenic, vproteolytically-digestible powder be: produced: thereby; Circulation of air having :a: relative i humidity of: ten per centror. less ata; temperature; between aboutaZOrrand about135. de rees: centigrade, most desirably.
  • While the. starting; material .folithepreparation of; the new gelatin; powder; maycomprise. either;- a gelatin'solutlon or gelatinfiake, fillilWhilQfihBf particular. starting, material may-be dried anct'.
  • the-synergistic effects of drying at-relatively higher temperatures as astep forthe attainment of-the proper 'physia cal properties is requisite.
  • 'Ihis step comprises: subjecting the. dry gelatin .flake or powder, to .a'. relatively high temperature above about Hide:- greescentigrade, for a;,relatively,len thy-period of time, e;g., fromaboutf20 to lyhours,.,preerly at 1 a temperaturebBtWeengabput ;1,62.:and; 191;. degrees .centigrade; (32.0; to 3f75 degrees Fahr en.-- heit)
  • This treatmentz has been found. to; pro
  • Example 1 One kilogram t :skimgelatin fiake is dissolved; in liters of warm water to make a 10-;per-centv gelatin solution. The solution .iscooled to -about 40 degrees centigrade and 10 milliliters-got-U. S,.-.P-.-'. 40 per. centformaldehydesolution is addedwith stirring. The solution isallowedto stand-at room temperature until a stiff gel;forins whereafter;
  • the jelly is cut into ;slabs,;of suitable size, preferablyless than oneinch thick, and-dried by; circu: lation of air -of;-l0 per; cent or:-less relativeqhumideity at a temperaturegof abeut,30degreesrcenti rad
  • This powder is finely pulverized and bolted to the desired particle size, less than 50 microns in diameter. After packaging in a. suitable container, the powder is sterilized. by heating in; dry air at degrees centigrade for four hours.
  • the powdered product is biologically absorbable and causes no foreign body reaction in surgical use.
  • the powder is suitably biologically absorbable and non-irritating 7 to incised human tissue.
  • a sterile, substantially; water-insoluble, nonantigenic, completely proteolytically digestible powder suitable forsurgical lubrication consisting essentially of gelatin that has been hardened to the-stage of substantial wa-ter-insolubility' and that has'thereafter been pulverized and subjected to heat treatment, whichpowderedmateria'l'is completely digestible within approximately 0.5
  • a pr sees-for the production of asubstantially water-insoluble; non-antigenic, completely proteolyticallydigestible powder suitable for sur-- gical" lubrication: which comprises: hardening" gelatin to a-state'of substantial water-insolubility andithereafter heating saidproductat a tem peraturebetween approximatelylS degrees and ;.approximately 191' degreescentigrade for" such period. that ,the product is :substantially waterinsolubler but still is completely: proteolyticallydigestible '1 5;- .A'. procession-the; production :of a-substamtheneround; toc ifine; powder. which-.-is;heated ugtiallyzwater ins0lub1e;..n0n-1antigenic,: completely- REFERENCES crrnn
  • the following references are of record in the file of this patent:

Landscapes

  • Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Materials Engineering (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Materials For Medical Uses (AREA)

Description

Patented May 9, 1950 SURGICAL GELATIN DUSTIN G POWDER AND PROCESS FOR PREPARING SAME John T. Correll, Kalamazoo, Mich., assignor to The Upjohn Company, Kalamazoo, Mich., a corporation of Michigan No Drawing. Application April 14, 1947, Serial No. 741,419
Claims. (Cl. 260-117) This invention relates to a powder, suitable for surgical use, which is absorbable by the bodies of living animals.
The technique of surgery, as developed through years of experience, requires the surgeon, after having thoroughly disinfected his hands, to wear rubber gloves during the actual manipulative performance. These rubber or surgical gloves are of a special construction, which is necessary according to the nature of their use. To allow snug fitting of the hand, the gloves must be extremely thin. This thinness, however, is disadvantageous in that it renders the gloves weak from a mechanical standpoint so that they are not capable of withstanding extensive pulling or stretching. To obviate tearing while they are in the process of being put on just before surgery, experience has shown that the gloves must be lubricated.
The most common lubricant for this use, until the present invention, has been a special sterile powdered inorganic talc. This talc, which is water-soluble and, by the nature of its physical structure, lubricating, allows the tight-fitting gloves to be fitted to the hand, and removed therefrom, without their rupture, and is therefore satisfactory for the surgeons immediate purpose, viz, donning the gloves Without their rupture or contamination. However, this talc is not entirely satisfactory from the standpoint of ulterior physiological effects upon the patient being treated.
It is well known that inert substances, foreign in composition to the body, exert a deleterious effect when allowed to remain in contact with the healing surfaces of an incision. This reaction, called a foreign-body reaction, instigates a permanent and progressive inflammation which may cause many complications, such as adhesions. Inert foreign bodies in the incision may also cause granulomatous lesions of the peritoneum, draining sinuses, scar nodules, and malfunctioning intestinal stomas.
It has been shown (Seelig, Verda, and Kidd, Jour. Am. Med. Assoc. 123, 950, 1943; Seelig, The Surgical Clinics of No. Am., Oct. 1944, Barnard Hospital Number; Seelig and Verda, Jour. Mount Sinai Hospital XII N0. 1, May-June 1945; Seelig, Jour. So. Med. Assoc. 38, 4'70, 1945; Lichtman, McDonald, Dixon, and Mann, Surg. Gync. and Obst. 83, 531, 1946; Antopol, Arch. Path. 16, 326, 1933; Erb, Surg. Gym. and. Obst. 60, 40, 1935) that the talc commonly used in surgical procedures acts as a foreign body, with the above-mentioned undesirable results. The need for a lubricant which can be used in the same manner as talc, but
which does not have the attendant undesirable properties of talc, has been recognized in the references already given. These references further show that various attempts to solve this problem have been made, but no success is indicated.
It is, therefore, an object of the present invention to provide a powder which is suitable for use as a lubricant of such surgical devices as rubber gloves, but which, being absorbable by the body fluids, does not effect complications which arise from the employment of an inert material. As the new powder is water-insoluble, it is neither dissolved by perspiration nor made tacky or sticky by exposure thereto. The product of this invention is a water-insoluble, sterile, non-toxic, non-antigenic, non-tissue irritating hardened gelatin powder which is absorbable by the animal body without residue or untoward side reactions, and which is capable of safe and satisfactory lubrication of rubber articles such as the aforementioned surgical gloves.
The proteolytically digestible powder of the invention is prepared by suitably hardening a gelatin, either before or after reduction to a powder. A gelatin solution may first be hardened either by the use of a chemical hardening agent, such as an aldehyde, or by heat, and thereafter subjected in either flake, slab, or powder form, to the synergistic action of a high-temperature treatment. Gelatin flake may be suitably hardened by merely heating the same, in its flake form or after further reduction to a powder, at a temperature above about 145 degrees centigrade for a period of time between about 20 and about hours.
The degree to which the gelatin is changed or hardened is of critical importance, for, if the change from the original gelatin is not sufficient, the resulting product will be water-soluble or partially water-soluble and the powder will lose a certain proportion of its lubricating properties when exposed to moisture. On the other hand, if the change or hardening be carried too far, the product will no longer be susceptible to proteolytie disintegration and absorption by the body fluids, and thus, not being absorbable by the body, will cause the formation of granulomas and adhesions in the same manner as any other foreign substance. Accordingly, to determine whether the product has been suitably hardened, it should be found to be water-insoluble and proteolytically digestible. The digestion time may be determined in a manner similar to that employed for determining the proteolytic absorbability of cat gut sutures, such as, for example, by exposure to either a 5.0 or 0.5 per cent pepsin solution, in which case proteolytic digestibility is usually satisfactory if complete within a period of about one-half hour and about six hours, respectively, for the two concentrations given. Beyond these limits, the product may. be unsuited. for the pre.-. scribed use.
The powder should not comprise any ingredients of an antigenic nature, but, while pure gelae tin with or without a minor; proportion. of aldehydic hardening agent is presentlynzonsidered' the; most satisfactory composition, other non-antigenic, sterile ingredients may beaddedjfi' l chi addition is considered desirable;
The hardening agent, if such is employed, may be of any suitable type, formaldehyde bein Dre, ferred. This aldehydic hardening agent may be; present in an amount not to exceed about three per cent by weight in the powdered product. Any other method of hardening a gelatin solution may be'employed, p ioy dedbnly thatthe, de.- sired water-insoluble., non-antigenic, vproteolytically-digestible powder be: produced: thereby; Circulation of air having :a: relative i humidity of: ten per centror. less ata; temperature; between aboutaZOrrand about135. de rees: centigrade, most desirably. at: about;.3.0 degrees centigrade'his' a. satisfactory. method ,of' drying partially-solidified, gelatin slabs, but spray-dryingbefore gelation of. the solution i is..complete-.may; be employedrif dc;- sired, and insome instances: is.:preferred.
While the. starting; material .folithepreparation of; the new gelatin; powder; maycomprise. either;- a gelatin'solutlon or gelatinfiake, fillilWhilQfihBf particular. starting, material may-be dried anct'.
hardened in any suitable manner, the-synergistic; effects of drying at-relatively higher temperatures as astep forthe attainment of-the proper 'physia cal properties is requisite. 'Ihis step; comprises: subjecting the. dry gelatin .flake or powder, to .a'. relatively high temperature above about Hide:- greescentigrade, for a;,relatively,len thy-period of time, e;g., fromaboutf20 to lyhours,.,preerly at 1 a temperaturebBtWeengabput ;1,62.:and; 191;. degrees .centigrade; (32.0; to 3f75 degrees Fahr en.-- heit) This treatmentzhas been found. to; pro
duce the. mostsuitably hardenedzor; denatured: gelatin powder; when; used: alone; or in. combine: tion with other steps. A combination. oi; the: formaldehyde treatment and: this heat denatur ing is .avery practioalmarmer of :producingthei product offthe presentinvention. The: finely" ivideo". gelatinpowder, whendesired to be. used:
as a lubricant for. rubber articles demandingsterility, should of course be sterilized, and such. isusually. accomplishedaby. heatin at ,elevated temperatures as-.illustrated in theexamples;
The following. examplesare given to-illustrate: the preparation of the-product ofthise-invention, but are in .no. way to be construed'as-limiting.
Example 1 One kilogram t :skimgelatin fiake is dissolved; in liters of warm water to make a 10-;per-centv gelatin solution. The solution .iscooled to -about 40 degrees centigrade and 10 milliliters-got-U. S,.-.P-.-'. 40 per. centformaldehydesolution is addedwith stirring. The solution isallowedto stand-at room temperature until a stiff gel;forins whereafter;
the jelly is cut into ;slabs,;of suitable size, preferablyless than oneinch thick, and-dried by; circu: lation of air -of;-l0 per; cent or:-less relativeqhumideity at a temperaturegof abeut,30degreesrcenti rad The; dried. hardened; elatin flakes.- are--.
at a temperature of about 145 degrees centigrade for between 15 and hours. This powder is finely pulverized and bolted to the desired particle size, less than 50 microns in diameter. After packaging in a. suitable container, the powder is sterilized. by heating in; dry air at degrees centigrade for four hours. The powdered product is biologically absorbable and causes no foreign body reaction in surgical use.
Example 2 powder-was then further pulverized and bolted= to the desired size, preferably 50 microns or less' in diameter, and packaged in suitable containers and sterilized, e;g., by heating in dry air to a temperature of 145' degreescentigrade fora period of" about four hours. The powder is suitably biologically absorbable and non-irritating 7 to incised human tissue.
Various modifications maybe made in the in-- vention without departing from thespiritor scope thereof; and it'is' to-be" understood that I- limit myself only as defined intheappended claims.
I clainr:
1. A sterile, substantially; water-insoluble, nonantigenic, completely proteolytically digestible powder suitable forsurgical lubrication consisting essentially of gelatin that has been hardened to the-stage of substantial wa-ter-insolubility' and that has'thereafter been pulverized and subjected to heat treatment, whichpowderedmateria'l'is completely digestible within approximately 0.5
hour in 21' 5 percent' and within-approximately6- hours in-a 0 .5 percent-aqueous pepsin solution.-
2; A sterile, substantially water-insoluble, nonantigenic, completely proteolytically digestible:- powder suitable for-surgical lubrication consistingessentially-of gelatin that has been hardenedby" treatment withlessthan approximately 3 percent by weight of formaldehyde in aqueous solution, thereafterdried'and pulverized and'subjected-to heat treatment until theproductis no' longersubstantially-soluble in water but still is scempletely digestible within approximately 0.5- hour: in a E'percent and-Within approximately 6' lio-ursina 0.5 percentaqueous solution of pepsin;
3". A-sterilepowder suitable for surgical lubri-- cation as-defined-inelaim Zand further charac terizeddn thatthe. individual particles thereof are of size: less than approximately 50 microns in diameter.
4: A pr sees-for the production of asubstantially water-insoluble; non-antigenic, completely proteolyticallydigestible powder suitable for sur-- gical" lubrication: which comprises: hardening" gelatin to a-state'of substantial water-insolubility andithereafter heating saidproductat a tem peraturebetween approximatelylS degrees and ;.approximately 191' degreescentigrade for" such period. that ,the product is :substantially waterinsolubler but still is completely: proteolyticallydigestible '1 5;- .A'. procession-the; production :of a-substamtheneround; toc ifine; powder. which-.-is;heated ugtiallyzwater=ins0lub1e;..n0n-1antigenic,: completely- REFERENCES crrnn The following references are of record in the file of this patent:
UNITED STATES PATENTS Number Name Date 658,747 Altschul Oct. 2, 1900 659,204 Brat Oct. 9, 1900 1,021,674 Horowitz Mar. 26, 1912 FOREIGN PATENTS Number Country Date 555,718 Germany July 27, 1932 Certificate of Correction Patent No. 2,507,244 May 9 1950: i 'f JOHN T. CORRELL It is hereby certified that error appears in the printed specification of the above numhered patent requiring correction as follows:
Column 1, line 22, for the hyphenated Word Water-soluble read water-insoluble THOMAS F. MURPHY,
Assistant Commissioner of Patents.

Claims (1)

1. A STERILE, SUBSTANTIALLY WATER-INSOLUBLE, NONANTIGENIC, COMPLETELY PROTEOLYTICALLY DIEGESTIBLE POWDER SUITABLE FOR SURGICAL LUBRICATION CONSISTING ESSENTIALLY OF GELATIN THAT HAS BEEN HARDENED TO THE STAGE OF SUBSTANTIAL WATER-INSOLUBILITY AND THAT HAS THEREAFTER BEEN PULVERIZED AND SUBJECTED TO HEAT TEATMENT, WHICH POWDERED MATERIAL IS COMPLETELY DIGESTIBLE WITHIN APPROXIMATELY 0.5 HOUR IN A 5 PERCENT AND WITHIN APPROXIMATELY 6 HOURS IN A 0.5 PERCCENT AQUEOUS PEPSIN SOLUTION.
US741419A 1947-04-14 1947-04-14 Surgical gelatin dusting powder and process for preparing same Expired - Lifetime US2507244A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US741419A US2507244A (en) 1947-04-14 1947-04-14 Surgical gelatin dusting powder and process for preparing same

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US741419A US2507244A (en) 1947-04-14 1947-04-14 Surgical gelatin dusting powder and process for preparing same

Publications (1)

Publication Number Publication Date
US2507244A true US2507244A (en) 1950-05-09

Family

ID=24980657

Family Applications (1)

Application Number Title Priority Date Filing Date
US741419A Expired - Lifetime US2507244A (en) 1947-04-14 1947-04-14 Surgical gelatin dusting powder and process for preparing same

Country Status (1)

Country Link
US (1) US2507244A (en)

Cited By (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3152976A (en) * 1961-09-21 1964-10-13 Ethicon Inc Preparation of collagenous materials
US3637411A (en) * 1968-04-12 1972-01-25 Dart Ind Inc Dual finish surgeon{3 s glove
US3793059A (en) * 1969-03-21 1974-02-19 Semperit Ag Buffer-treated rubber article for contact with skin
US4152783A (en) * 1977-10-19 1979-05-08 American Hospital Supply Corporation Lubricant for surgeon's gloves and method of applying same
US4292972A (en) * 1980-07-09 1981-10-06 E. R. Squibb & Sons, Inc. Lyophilized hydrocolloio foam
US4668224A (en) * 1983-10-24 1987-05-26 Warner-Lambert Company Oxidized cellulose as a medical lubricant
US4773902A (en) * 1983-10-24 1988-09-27 Deseret Medical, Inc. Oxidized cellulose as a medical lubricant
US5447966A (en) * 1988-07-19 1995-09-05 United States Surgical Corporation Treating bioabsorbable surgical articles by coating with glycerine, polalkyleneoxide block copolymer and gelatin
US6071301A (en) * 1998-05-01 2000-06-06 Sub Q., Inc. Device and method for facilitating hemostasis of a biopsy tract
US6162192A (en) * 1998-05-01 2000-12-19 Sub Q, Inc. System and method for facilitating hemostasis of blood vessel punctures with absorbable sponge
US6183497B1 (en) 1998-05-01 2001-02-06 Sub-Q, Inc. Absorbable sponge with contrasting agent
US6200328B1 (en) 1998-05-01 2001-03-13 Sub Q, Incorporated Device and method for facilitating hemostasis of a biopsy tract
US6315753B1 (en) 1998-05-01 2001-11-13 Sub-Q, Inc. System and method for facilitating hemostasis of blood vessel punctures with absorbable sponge
US20020156495A1 (en) * 1995-09-15 2002-10-24 Rodney Brenneman Apparatus and method for percutaneous sealing of blood vessel punctures
US20020193448A1 (en) * 1996-08-27 2002-12-19 Wallace Donald G. Fragmented polymeric compositions and methods for their use
US20020190226A1 (en) * 2001-03-12 2002-12-19 Mark Ashby Methods for sterilizing cross-linked gelatin compositions
US6540735B1 (en) 2000-05-12 2003-04-01 Sub-Q, Inc. System and method for facilitating hemostasis of blood vessel punctures with absorbable sponge
US20030064109A1 (en) * 2001-07-17 2003-04-03 Zhen Qian Dry hemostatic compositions and methods for their preparation
US6544236B1 (en) 1999-02-10 2003-04-08 Sub-Q, Incorporated Device, system and method for improving delivery of hemostatic material
US6610026B2 (en) 1998-05-01 2003-08-26 Sub-Q, Inc. Method of hydrating a sponge material for delivery to a body
US20040019330A1 (en) * 2001-11-08 2004-01-29 Sub-Q, Inc., A California Corporation Sheath based blood vessel puncture locator and depth indicator
US20040102730A1 (en) * 2002-10-22 2004-05-27 Davis Thomas P. System and method for facilitating hemostasis of blood vessel punctures with absorbable sponge
US20040158287A1 (en) * 2000-07-14 2004-08-12 Cragg Andrew H. Sheath-mounted arterial plug delivery device
US20040176723A1 (en) * 2001-11-08 2004-09-09 Sing Eduardo Chi Pledget-handling system and method for delivering hemostasis promoting material to a blood vessel puncture site by fluid pressure
US6846320B2 (en) 1998-05-01 2005-01-25 Sub-Q, Inc. Device and method for facilitating hemostasis of a biopsy tract
US20050033360A1 (en) * 2001-11-08 2005-02-10 Sing Eduardo Chi Pledget-handling system and method for delivering hemostasis promoting material to a blood vessel puncture site by fluid pressure
US20050037088A1 (en) * 2003-08-07 2005-02-17 Pendharkar Sanyog M. Process of making flowable hemostatic compositions and devices containing such compositions
US6863680B2 (en) 2001-11-08 2005-03-08 Sub-Q, Inc. System and method for delivering hemostasis promoting material to a blood vessel puncture site by fluid pressure
US20050171001A1 (en) * 2004-01-30 2005-08-04 Pendharkar Sanyog M. Hemostatic compositions and devices
US20050284809A1 (en) * 2004-06-29 2005-12-29 Looney Dwayne L Hemostatic compositions and devices
US6984219B2 (en) 1999-09-23 2006-01-10 Mark Ashby Depth and puncture control for blood vessel hemostasis system
US7008440B2 (en) 2001-11-08 2006-03-07 Sub-Q, Inc. System and method for delivering hemostasis promoting material to a blood vessel puncture site by fluid pressure
US7029489B1 (en) 2001-05-18 2006-04-18 Sub-Q, Inc. System and method for delivering hemostasis promoting material to a blood vessel puncture site
US7037322B1 (en) 2001-11-08 2006-05-02 Sub-Q, Inc. System and method for delivering hemostasis promoting material to a blood vessel puncture with a staging tube
US20060127488A1 (en) * 2003-08-07 2006-06-15 Pendharkar Sanyog M Process of making flowable hemostatic compositions and devices containing such compositions
US20060167561A1 (en) * 2003-06-05 2006-07-27 Johann Odar Methods for repairing and regenerating human dura mater
US7201725B1 (en) 2000-09-25 2007-04-10 Sub-Q, Inc. Device and method for determining a depth of an incision
US20070096354A1 (en) * 2003-08-07 2007-05-03 Gabel Jonathan B Process of making flowable hemostatic compositions and devices containing such compositions
US7335219B1 (en) 2002-11-04 2008-02-26 Sub-Q, Inc. Hemostatic device including a capsule
US20080076722A1 (en) * 2006-09-27 2008-03-27 Hemostasis, Llc Hemostatic Agent and Method
US20080082084A1 (en) * 2006-09-29 2008-04-03 Hemostasis, Llc System and Method to Vent Gas From a Body Cavity
US20080085316A1 (en) * 1996-08-27 2008-04-10 Baxter Healthcare Corporation Dry hemostatic compositions and methods for their preparation
US20080187591A1 (en) * 2006-08-02 2008-08-07 Baxter International, Inc. Rapidly acting dry sealant and methods for use and manufacture
US20090226391A1 (en) * 2008-03-04 2009-09-10 Hemostasis, Llc Hemostatic Sponge and Method of Manufacture
US7625352B1 (en) 1998-05-01 2009-12-01 Sub-Q, Inc. Depth and puncture control for system for hemostasis of blood vessel
US20100028309A1 (en) * 2006-05-31 2010-02-04 Baxter International Inc. Method for directed cell in-growth and controlled tissue regeneration in spinal surgery
US7695492B1 (en) 1999-09-23 2010-04-13 Boston Scientific Scimed, Inc. Enhanced bleed back system
US20100292717A1 (en) * 2009-05-18 2010-11-18 Baxter International Inc. Method for the improvement of mesh implant biocompatibility
US20100318048A1 (en) * 2009-06-16 2010-12-16 Baxter International Inc. Hemostatic sponge
US7875043B1 (en) 2003-12-09 2011-01-25 Sub-Q, Inc. Cinching loop
US20110052663A1 (en) * 2009-09-01 2011-03-03 Hemostasis, Llc Hemostatic Sponge with Enzyme and Method of Manufacture
US7955353B1 (en) 2002-11-04 2011-06-07 Sub-Q, Inc. Dissolvable closure device
US20110202026A1 (en) * 2009-12-16 2011-08-18 Baxter International Inc. Hemostatic sponge
US8187625B2 (en) 2001-03-12 2012-05-29 Boston Scientific Scimed, Inc. Cross-linked gelatin composition comprising a wetting agent
US8303981B2 (en) 1996-08-27 2012-11-06 Baxter International Inc. Fragmented polymeric compositions and methods for their use
US8317821B1 (en) 2002-11-04 2012-11-27 Boston Scientific Scimed, Inc. Release mechanism
US8585646B2 (en) 2008-03-03 2013-11-19 Lexion Medical, Llc System and method to vent gas from a body cavity
US8603511B2 (en) 1996-08-27 2013-12-10 Baxter International, Inc. Fragmented polymeric compositions and methods for their use
US8703170B2 (en) 2010-04-07 2014-04-22 Baxter International Inc. Hemostatic sponge
US8790698B2 (en) 2007-10-30 2014-07-29 Baxter International Inc. Use of a regenerative biofunctional collagen biomatrix for treating visceral or parietal defects
US8940335B2 (en) 2010-06-01 2015-01-27 Baxter International Inc. Process for making dry and stable hemostatic compositions
US9084728B2 (en) 2010-06-01 2015-07-21 Baxter International Inc. Process for making dry and stable hemostatic compositions
US9265858B2 (en) 2012-06-12 2016-02-23 Ferrosan Medical Devices A/S Dry haemostatic composition
US9408945B2 (en) 2010-06-01 2016-08-09 Baxter International Inc. Process for making dry and stable hemostatic compositions
US9533069B2 (en) 2008-02-29 2017-01-03 Ferrosan Medical Devices A/S Device for promotion of hemostasis and/or wound healing
US9724078B2 (en) 2013-06-21 2017-08-08 Ferrosan Medical Devices A/S Vacuum expanded dry composition and syringe for retaining same
US9821025B2 (en) 2011-10-11 2017-11-21 Baxter International Inc. Hemostatic compositions
US9833541B2 (en) 2011-10-27 2017-12-05 Baxter International Inc. Hemostatic compositions
US10111980B2 (en) 2013-12-11 2018-10-30 Ferrosan Medical Devices A/S Dry composition comprising an extrusion enhancer
US10322170B2 (en) 2011-10-11 2019-06-18 Baxter International Inc. Hemostatic compositions
US10653837B2 (en) 2014-12-24 2020-05-19 Ferrosan Medical Devices A/S Syringe for retaining and mixing first and second substances
US10918796B2 (en) 2015-07-03 2021-02-16 Ferrosan Medical Devices A/S Syringe for mixing two components and for retaining a vacuum in a storage condition
US11046818B2 (en) 2014-10-13 2021-06-29 Ferrosan Medical Devices A/S Dry composition for use in haemostasis and wound healing
US11109849B2 (en) 2012-03-06 2021-09-07 Ferrosan Medical Devices A/S Pressurized container containing haemostatic paste
US11679177B2 (en) 2017-08-08 2023-06-20 Baxter International Inc. Polymeric compositions, delivery devices, and methods
US11801324B2 (en) 2018-05-09 2023-10-31 Ferrosan Medical Devices A/S Method for preparing a haemostatic composition

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US658747A (en) * 1898-11-11 1900-10-02 Anilin Fabrikation Ag Compound of gelatin and tannin and process of producing same.
US659204A (en) * 1900-08-09 1900-10-09 Actiengesellschaft Fuer Anilin Fabrikation Bromo-tannin-gelatin compound.
US1021674A (en) * 1910-03-23 1912-03-26 Arthur Horowitz Medicinal tablet.
DE555718C (en) * 1931-02-05 1932-07-27 Goedecke & Co Chem Fabrik A G Process for the production of easily disintegrating tablets

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US658747A (en) * 1898-11-11 1900-10-02 Anilin Fabrikation Ag Compound of gelatin and tannin and process of producing same.
US659204A (en) * 1900-08-09 1900-10-09 Actiengesellschaft Fuer Anilin Fabrikation Bromo-tannin-gelatin compound.
US1021674A (en) * 1910-03-23 1912-03-26 Arthur Horowitz Medicinal tablet.
DE555718C (en) * 1931-02-05 1932-07-27 Goedecke & Co Chem Fabrik A G Process for the production of easily disintegrating tablets

Cited By (157)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3152976A (en) * 1961-09-21 1964-10-13 Ethicon Inc Preparation of collagenous materials
US3637411A (en) * 1968-04-12 1972-01-25 Dart Ind Inc Dual finish surgeon{3 s glove
US3793059A (en) * 1969-03-21 1974-02-19 Semperit Ag Buffer-treated rubber article for contact with skin
US4152783A (en) * 1977-10-19 1979-05-08 American Hospital Supply Corporation Lubricant for surgeon's gloves and method of applying same
US4292972A (en) * 1980-07-09 1981-10-06 E. R. Squibb & Sons, Inc. Lyophilized hydrocolloio foam
US4668224A (en) * 1983-10-24 1987-05-26 Warner-Lambert Company Oxidized cellulose as a medical lubricant
US4773902A (en) * 1983-10-24 1988-09-27 Deseret Medical, Inc. Oxidized cellulose as a medical lubricant
US5447966A (en) * 1988-07-19 1995-09-05 United States Surgical Corporation Treating bioabsorbable surgical articles by coating with glycerine, polalkyleneoxide block copolymer and gelatin
US20020156495A1 (en) * 1995-09-15 2002-10-24 Rodney Brenneman Apparatus and method for percutaneous sealing of blood vessel punctures
US7175646B2 (en) 1995-09-15 2007-02-13 Boston Scientific Scimed, Inc. Apparatus and method for percutaneous sealing of blood vessel punctures
US20080085316A1 (en) * 1996-08-27 2008-04-10 Baxter Healthcare Corporation Dry hemostatic compositions and methods for their preparation
US7871637B2 (en) 1996-08-27 2011-01-18 Baxter International Inc. Dry hemostatic compositions and methods for their preparation
US8303981B2 (en) 1996-08-27 2012-11-06 Baxter International Inc. Fragmented polymeric compositions and methods for their use
US8357378B2 (en) 1996-08-27 2013-01-22 Baxter International Inc. Fragmented polymeric compositions and methods for their use
US8512729B2 (en) 1996-08-27 2013-08-20 Baxter International Inc. Fragmented polymeric compositions and methods for their use
US8603511B2 (en) 1996-08-27 2013-12-10 Baxter International, Inc. Fragmented polymeric compositions and methods for their use
US20020193448A1 (en) * 1996-08-27 2002-12-19 Wallace Donald G. Fragmented polymeric compositions and methods for their use
US7753872B2 (en) 1998-05-01 2010-07-13 Boston Scientific Scimed, Inc. Device, system and method for improving delivery of hemostatic material
US20050059080A1 (en) * 1998-05-01 2005-03-17 Sing Eduardo Chi Absorbable sponge with contrasting agent
US6527734B2 (en) 1998-05-01 2003-03-04 Sub-Q, Inc. System and method for facilitating hemostasis of blood vessel punctures with absorbable sponge
US6071301A (en) * 1998-05-01 2000-06-06 Sub Q., Inc. Device and method for facilitating hemostasis of a biopsy tract
US6162192A (en) * 1998-05-01 2000-12-19 Sub Q, Inc. System and method for facilitating hemostasis of blood vessel punctures with absorbable sponge
US7611479B2 (en) 1998-05-01 2009-11-03 Sub-Q, Inc. System and method for facilitating hemostasis of blood vessel punctures with absorbable sponge
US20030088271A1 (en) * 1998-05-01 2003-05-08 Cragg Andrew M. System and method for facilitating hemostasis of blood vessel punctures with absorbable sponge
US20030135237A1 (en) * 1998-05-01 2003-07-17 Cragg Andrew H. Device, system and method for improving delivery of hemostatic material
US6610026B2 (en) 1998-05-01 2003-08-26 Sub-Q, Inc. Method of hydrating a sponge material for delivery to a body
US7618567B2 (en) 1998-05-01 2009-11-17 Boston Scientific Scimed, Inc. Absorbable sponge with contrasting agent
US6447534B2 (en) 1998-05-01 2002-09-10 Sub-Q, Inc. Device and method for facilitating hemostasis of a biopsy tract
US7625352B1 (en) 1998-05-01 2009-12-01 Sub-Q, Inc. Depth and puncture control for system for hemostasis of blood vessel
US20100029908A1 (en) * 1998-05-01 2010-02-04 Boston Scientific Scimed, Inc. Absorbable sponge with contrasting agent
US6440153B2 (en) 1998-05-01 2002-08-27 Sub-Q, Inc. Device and method for facilitating hemostasis of a biopsy tract
US6846320B2 (en) 1998-05-01 2005-01-25 Sub-Q, Inc. Device and method for facilitating hemostasis of a biopsy tract
US7048710B1 (en) 1998-05-01 2006-05-23 Sub-Q, Inc. System and method for facilitating hemostasis of blood vessel punctures with absorbable sponge
US6440151B1 (en) 1998-05-01 2002-08-27 Sub-Q, Inc. Device and method for facilitating hemostasis of a biopsy tract
US6315753B1 (en) 1998-05-01 2001-11-13 Sub-Q, Inc. System and method for facilitating hemostasis of blood vessel punctures with absorbable sponge
US20100036414A1 (en) * 1998-05-01 2010-02-11 Sub-Q, Inc. System and method for facilitating hemostasis of blood vessel punctures with absorbable sponge
US6183497B1 (en) 1998-05-01 2001-02-06 Sub-Q, Inc. Absorbable sponge with contrasting agent
US20050113737A1 (en) * 1998-05-01 2005-05-26 Mark Ashby Device and method for facilitating hemostasis of a biopsy tract
US8050741B2 (en) 1998-05-01 2011-11-01 Boston Scientific Scimed, Inc. Device and method for facilitating hemostasis of a biopsy tract
US6200328B1 (en) 1998-05-01 2001-03-13 Sub Q, Incorporated Device and method for facilitating hemostasis of a biopsy tract
US6544236B1 (en) 1999-02-10 2003-04-08 Sub-Q, Incorporated Device, system and method for improving delivery of hemostatic material
US6984219B2 (en) 1999-09-23 2006-01-10 Mark Ashby Depth and puncture control for blood vessel hemostasis system
US7695492B1 (en) 1999-09-23 2010-04-13 Boston Scientific Scimed, Inc. Enhanced bleed back system
US6964658B2 (en) 2000-05-12 2005-11-15 Sub-Q, Inc. System and method for facilitating hemostasis of blood vessel punctures with absorbable sponge
US6540735B1 (en) 2000-05-12 2003-04-01 Sub-Q, Inc. System and method for facilitating hemostasis of blood vessel punctures with absorbable sponge
US8696702B2 (en) 2000-07-14 2014-04-15 Boston Scientific Scimed, Inc. Sheath-mounted arterial plug delivery device
US20100049245A1 (en) * 2000-07-14 2010-02-25 Boston Scientific Scimed, Inc. Sheath-mounted arterial plug delivery device
US20040158287A1 (en) * 2000-07-14 2004-08-12 Cragg Andrew H. Sheath-mounted arterial plug delivery device
US7621936B2 (en) 2000-07-14 2009-11-24 Boston Scientific Scimed, Inc. Sheath-mounted arterial plug delivery device
US7201725B1 (en) 2000-09-25 2007-04-10 Sub-Q, Inc. Device and method for determining a depth of an incision
US8187625B2 (en) 2001-03-12 2012-05-29 Boston Scientific Scimed, Inc. Cross-linked gelatin composition comprising a wetting agent
US6849232B2 (en) 2001-03-12 2005-02-01 Sub-Q, Inc. Methods for sterilizing cross-linked gelatin compositions
US8524270B2 (en) 2001-03-12 2013-09-03 Boston Scientific Scimed, Inc. Cross-linked gelatin composition coated with a wetting agent
US7264772B2 (en) 2001-03-12 2007-09-04 Boston Scientific Scimed, Inc. Methods for sterilizing cross-linked gelatin compositions
US8821918B2 (en) 2001-03-12 2014-09-02 Boston Scientific Scimed Inc. Cross-linked gelatin composition comprising a wetting agent
US20020190226A1 (en) * 2001-03-12 2002-12-19 Mark Ashby Methods for sterilizing cross-linked gelatin compositions
US7029489B1 (en) 2001-05-18 2006-04-18 Sub-Q, Inc. System and method for delivering hemostasis promoting material to a blood vessel puncture site
EP1414370A4 (en) * 2001-07-17 2005-11-09 Baxter Int Dry hemostatic compositions and methods for their preparation
US7547446B2 (en) 2001-07-17 2009-06-16 Baxter International, Inc. Dry hemostatic compositions and methods for their preparation
AU2002345846B2 (en) * 2001-07-17 2007-08-23 Baxter Healthcare S.A. Dry hemostatic compositions and methods for their preparation
US8092820B2 (en) 2001-07-17 2012-01-10 Baxter International Inc. Dry hemostatic compositions and methods for their preparation
US20070248685A1 (en) * 2001-07-17 2007-10-25 Fusion Medical Technologies, Inc. Dry hemostatic compositions and methods for their preparation
EP1803417A1 (en) * 2001-07-17 2007-07-04 Baxter International Inc. Dry hemostatic compositions and methods for their preparation
US20030064109A1 (en) * 2001-07-17 2003-04-03 Zhen Qian Dry hemostatic compositions and methods for their preparation
US8383141B2 (en) 2001-07-17 2013-02-26 Baxter International Inc. Dry hemostatic compositions and methods for their preparation
US20090227779A1 (en) * 2001-07-17 2009-09-10 Baxter International, Inc. Dry hemostatic compositions and methods for their preparation
EP1414370A1 (en) * 2001-07-17 2004-05-06 Baxter International Inc. Dry hemostatic compositions and methods for their preparation
US7435425B2 (en) 2001-07-17 2008-10-14 Baxter International, Inc. Dry hemostatic compositions and methods for their preparation
US20080286376A1 (en) * 2001-07-17 2008-11-20 Fusion Medical Technologies, Inc. Dry hemostatic compositions and methods for their preparation
US20040019330A1 (en) * 2001-11-08 2004-01-29 Sub-Q, Inc., A California Corporation Sheath based blood vessel puncture locator and depth indicator
US7037323B2 (en) 2001-11-08 2006-05-02 Sub-Q, Inc. Pledget-handling system and method for delivering hemostasis promoting material to a blood vessel puncture site by fluid pressure
US20040176723A1 (en) * 2001-11-08 2004-09-09 Sing Eduardo Chi Pledget-handling system and method for delivering hemostasis promoting material to a blood vessel puncture site by fluid pressure
US7192436B2 (en) 2001-11-08 2007-03-20 Sub-Q, Inc. Pledget-handling system and method for delivering hemostasis promoting material to a blood vessel puncture site by fluid pressure
US7008440B2 (en) 2001-11-08 2006-03-07 Sub-Q, Inc. System and method for delivering hemostasis promoting material to a blood vessel puncture site by fluid pressure
US20050033360A1 (en) * 2001-11-08 2005-02-10 Sing Eduardo Chi Pledget-handling system and method for delivering hemostasis promoting material to a blood vessel puncture site by fluid pressure
US7025748B2 (en) 2001-11-08 2006-04-11 Boston Scientific Scimed, Inc. Sheath based blood vessel puncture locator and depth indicator
US6863680B2 (en) 2001-11-08 2005-03-08 Sub-Q, Inc. System and method for delivering hemostasis promoting material to a blood vessel puncture site by fluid pressure
US7037322B1 (en) 2001-11-08 2006-05-02 Sub-Q, Inc. System and method for delivering hemostasis promoting material to a blood vessel puncture with a staging tube
US20040102730A1 (en) * 2002-10-22 2004-05-27 Davis Thomas P. System and method for facilitating hemostasis of blood vessel punctures with absorbable sponge
US7955353B1 (en) 2002-11-04 2011-06-07 Sub-Q, Inc. Dissolvable closure device
US8317821B1 (en) 2002-11-04 2012-11-27 Boston Scientific Scimed, Inc. Release mechanism
US7335219B1 (en) 2002-11-04 2008-02-26 Sub-Q, Inc. Hemostatic device including a capsule
US20060167561A1 (en) * 2003-06-05 2006-07-27 Johann Odar Methods for repairing and regenerating human dura mater
US8834864B2 (en) 2003-06-05 2014-09-16 Baxter International Inc. Methods for repairing and regenerating human dura mater
US7718412B2 (en) 2003-08-07 2010-05-18 Ethicon, Inc. Hemostatic compositions containing sterile thrombin
US20060110381A1 (en) * 2003-08-07 2006-05-25 Pendharkar Sanyog M Hemostatic compositions containing sterile thrombin
US9005609B2 (en) 2003-08-07 2015-04-14 Ethicon, Inc. Hemostatic compositions containing sterile thrombin
US7833965B2 (en) 2003-08-07 2010-11-16 Ethicon, Inc. Process of making flowable hemostatic compositions and devices containing such compositions
US8440225B2 (en) 2003-08-07 2013-05-14 Ethicon, Inc. Process of making flowable hemostatic compositions and devices containing such compositions
US8551941B2 (en) 2003-08-07 2013-10-08 Ethicon, Inc. Process of making flowable hemostatic compositions and devices containing such compositions
US20110027378A1 (en) * 2003-08-07 2011-02-03 Ethicon, Inc. Process of making flowable hemostatic compositions and devices containing such compositions
US20070096354A1 (en) * 2003-08-07 2007-05-03 Gabel Jonathan B Process of making flowable hemostatic compositions and devices containing such compositions
US7927626B2 (en) 2003-08-07 2011-04-19 Ethicon, Inc. Process of making flowable hemostatic compositions and devices containing such compositions
US20100230845A9 (en) * 2003-08-07 2010-09-16 Gabel Jonathan B Process of making flowable hemostatic compositions and devices containing such compositions
US20060204490A1 (en) * 2003-08-07 2006-09-14 Pendharkar Sanyog M Hemostatic compositions containing sterile thrombin
US20060127488A1 (en) * 2003-08-07 2006-06-15 Pendharkar Sanyog M Process of making flowable hemostatic compositions and devices containing such compositions
US20100183582A1 (en) * 2003-08-07 2010-07-22 Ethicon, Inc. Hemostatic compositions containing sterile thrombin
US20050037088A1 (en) * 2003-08-07 2005-02-17 Pendharkar Sanyog M. Process of making flowable hemostatic compositions and devices containing such compositions
US7875043B1 (en) 2003-12-09 2011-01-25 Sub-Q, Inc. Cinching loop
US7109163B2 (en) 2004-01-30 2006-09-19 Ethicon, Inc. Hemostatic compositions and devices
US20050171001A1 (en) * 2004-01-30 2005-08-04 Pendharkar Sanyog M. Hemostatic compositions and devices
US8119160B2 (en) 2004-06-29 2012-02-21 Ethicon, Inc. Hemostatic compositions and devices
US20050284809A1 (en) * 2004-06-29 2005-12-29 Looney Dwayne L Hemostatic compositions and devices
US20100028309A1 (en) * 2006-05-31 2010-02-04 Baxter International Inc. Method for directed cell in-growth and controlled tissue regeneration in spinal surgery
US8703122B2 (en) 2006-05-31 2014-04-22 Baxter International Inc. Method for directed cell in-growth and controlled tissue regeneration in spinal surgery
US8962025B2 (en) 2006-08-02 2015-02-24 Baxter International Inc. Rapidly acting dry sealant and methods for use and manufacture
US9114172B2 (en) 2006-08-02 2015-08-25 Baxter International Inc. Rapidly acting dry sealant and methods for use and manufacture
US20080187591A1 (en) * 2006-08-02 2008-08-07 Baxter International, Inc. Rapidly acting dry sealant and methods for use and manufacture
US20080076722A1 (en) * 2006-09-27 2008-03-27 Hemostasis, Llc Hemostatic Agent and Method
US8623842B2 (en) 2006-09-27 2014-01-07 Hemostasis, Llc Hemostatic agent and method
US10744310B2 (en) 2006-09-27 2020-08-18 Hemostasis, Llc Hemostatic agent and method
US9649482B2 (en) 2006-09-27 2017-05-16 Hemostasis, Llc Hemostatic agent and method
US8414550B2 (en) 2006-09-29 2013-04-09 Lexion Medical, Llc System and method to vent gas from a body cavity
US8608715B2 (en) 2006-09-29 2013-12-17 Lexion Medical, Llc System and method to vent gas from a body cavity
US20080082084A1 (en) * 2006-09-29 2008-04-03 Hemostasis, Llc System and Method to Vent Gas From a Body Cavity
US8790698B2 (en) 2007-10-30 2014-07-29 Baxter International Inc. Use of a regenerative biofunctional collagen biomatrix for treating visceral or parietal defects
US9533069B2 (en) 2008-02-29 2017-01-03 Ferrosan Medical Devices A/S Device for promotion of hemostasis and/or wound healing
US9821095B2 (en) 2008-03-03 2017-11-21 Lexion Medical, Llc System and method to vent gas from a body cavity
US8585646B2 (en) 2008-03-03 2013-11-19 Lexion Medical, Llc System and method to vent gas from a body cavity
US20090226391A1 (en) * 2008-03-04 2009-09-10 Hemostasis, Llc Hemostatic Sponge and Method of Manufacture
US9061087B2 (en) 2008-03-04 2015-06-23 Hemostasis, Llc Method of making a hemostatic sponge wound dressing comprising subjecting the sponge to water vapor
US9993298B2 (en) 2009-05-18 2018-06-12 Baxter International Inc. Method for the improvement of mesh implant biocompatibility
US20100292717A1 (en) * 2009-05-18 2010-11-18 Baxter International Inc. Method for the improvement of mesh implant biocompatibility
US9039783B2 (en) 2009-05-18 2015-05-26 Baxter International, Inc. Method for the improvement of mesh implant biocompatibility
US20100318048A1 (en) * 2009-06-16 2010-12-16 Baxter International Inc. Hemostatic sponge
US9162006B2 (en) 2009-06-16 2015-10-20 Baxter International Inc. Hemostatic sponge
US20110052663A1 (en) * 2009-09-01 2011-03-03 Hemostasis, Llc Hemostatic Sponge with Enzyme and Method of Manufacture
US9517287B2 (en) 2009-12-16 2016-12-13 Baxter International, Inc. Hemostatic sponge
US9872934B2 (en) 2009-12-16 2018-01-23 Baxter International Inc. Hemostatic sponge
US20110202026A1 (en) * 2009-12-16 2011-08-18 Baxter International Inc. Hemostatic sponge
US8771258B2 (en) 2009-12-16 2014-07-08 Baxter International Inc. Hemostatic sponge
US11071804B2 (en) 2009-12-16 2021-07-27 Baxter International Inc. Hemostatic sponge
US11478566B2 (en) 2010-04-07 2022-10-25 Baxter International Inc. Hemostatic sponge
US9375505B2 (en) 2010-04-07 2016-06-28 Baxter International Inc. Hemostatic sponge
US8703170B2 (en) 2010-04-07 2014-04-22 Baxter International Inc. Hemostatic sponge
US10441674B2 (en) 2010-04-07 2019-10-15 Baxter International Inc. Hemostatic sponge
US8940335B2 (en) 2010-06-01 2015-01-27 Baxter International Inc. Process for making dry and stable hemostatic compositions
US9084728B2 (en) 2010-06-01 2015-07-21 Baxter International Inc. Process for making dry and stable hemostatic compositions
US10994045B2 (en) 2010-06-01 2021-05-04 Baxter International Inc. Process for making dry and stable hemostatic compositions
US10245348B2 (en) 2010-06-01 2019-04-02 Baxter International Inc. Process for making dry and stable hemostatic compositions
US9408945B2 (en) 2010-06-01 2016-08-09 Baxter International Inc. Process for making dry and stable hemostatic compositions
US9821025B2 (en) 2011-10-11 2017-11-21 Baxter International Inc. Hemostatic compositions
US10322170B2 (en) 2011-10-11 2019-06-18 Baxter International Inc. Hemostatic compositions
US9833541B2 (en) 2011-10-27 2017-12-05 Baxter International Inc. Hemostatic compositions
US11109849B2 (en) 2012-03-06 2021-09-07 Ferrosan Medical Devices A/S Pressurized container containing haemostatic paste
US9999703B2 (en) 2012-06-12 2018-06-19 Ferrosan Medical Devices A/S Dry haemostatic composition
US10799611B2 (en) 2012-06-12 2020-10-13 Ferrosan Medical Devices A/S Dry haemostatic composition
US9265858B2 (en) 2012-06-12 2016-02-23 Ferrosan Medical Devices A/S Dry haemostatic composition
US10595837B2 (en) 2013-06-21 2020-03-24 Ferrosan Medical Devices A/S Vacuum expanded dry composition and syringe for retaining same
US9724078B2 (en) 2013-06-21 2017-08-08 Ferrosan Medical Devices A/S Vacuum expanded dry composition and syringe for retaining same
US10111980B2 (en) 2013-12-11 2018-10-30 Ferrosan Medical Devices A/S Dry composition comprising an extrusion enhancer
US11103616B2 (en) 2013-12-11 2021-08-31 Ferrosan Medical Devices A/S Dry composition comprising an extrusion enhancer
US11046818B2 (en) 2014-10-13 2021-06-29 Ferrosan Medical Devices A/S Dry composition for use in haemostasis and wound healing
US10653837B2 (en) 2014-12-24 2020-05-19 Ferrosan Medical Devices A/S Syringe for retaining and mixing first and second substances
US10918796B2 (en) 2015-07-03 2021-02-16 Ferrosan Medical Devices A/S Syringe for mixing two components and for retaining a vacuum in a storage condition
US11679177B2 (en) 2017-08-08 2023-06-20 Baxter International Inc. Polymeric compositions, delivery devices, and methods
US11801324B2 (en) 2018-05-09 2023-10-31 Ferrosan Medical Devices A/S Method for preparing a haemostatic composition

Similar Documents

Publication Publication Date Title
US2507244A (en) Surgical gelatin dusting powder and process for preparing same
US4587268A (en) Treatment of osteitis
US3728739A (en) Sterile surgical gloves
JPS63115561A (en) Gamma ray sterilization of polyvinyl alcohol gel
US3558771A (en) Process for using eggshell compositions for promoting wound healing
US4883664A (en) Medicinal salve
JP3148215B2 (en) Antimicrobial products, their manufacturing methods and applications
JENKINS et al. Gelatin sponge, a new hemostatic substance: Studies on absorbability
US4913904A (en) Ophthalmological collagen coverings
US2579367A (en) Bandage
EP0050215B1 (en) Modification of polyglycolic acid to achieve variable in-vivo physical properties
Lee et al. Leeches: controlled trial in venous compromised rat epigastric flaps
AU3151499A (en) Method for sterilising native collagen in liquid medium, resulting native collagen, compositions containing same and uses
EP1813294B1 (en) Adhesion preventive and method of preventing adhesion
US3810458A (en) Minimizing tissue reaction to glove powder
US2621333A (en) Powder lubricated surgeon's rubber glove
CN112190768A (en) Postoperative anti-adhesion gel for uterine cavity, preparation method and application thereof
Totre et al. Properties and hemostatic application of gelatin
JPH07206888A (en) Placenta extract and its preparation
JP2004123576A (en) Sustained release preparation containing platelet-rich plasma
CN106913899A (en) Plant polyose styptic sponge is prepared using secondary freezing
CN112138203B (en) Bone hemostatic material
CN107715167A (en) Chitosan-based hemostatic paste and preparation method as bone wax substitute
JPS5861744A (en) Implant material for repairing living body
JPH04500799A (en) Copolymer of vinyl acetate and vinyl alcohol crosslinked with glutaraldehyde, method for producing the same, and pharmaceuticals based on the same